Epizyme jumps 53% after IPO; Kamada rises 9.2%
This article was originally published in Scrip
Executive Summary
Epizyme closed 53.3% higher than its $15 initial public offering price at the end of its first day of trading, stealing the spotlight from another US first-time offering on 31 May by the Israeli biopharma company Kamada.